Related Experiment Video
Updated: Sep 20, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Pathogenicity of GB virus C on virus hepatitis and hemodialysis patients
Wan-Fu Zhu1, Li-Min Yin, Peng Li
1Department of Microbiology, School of Basic Medical Sciences, Peking University, Beijing 100083, China. zhuwanfu@sun.bjmu.edu.cn
Insights
GB virus C (GBV-C) does not appear to cause liver damage or affect hepatitis B and C patient outcomes. This study indicates GBV-C may not be a significant hepatitis virus.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis B and C are significant causes of liver disease worldwide.
- The role of GB virus C (GBV-C) in liver pathogenicity and its impact on co-infections remain areas of investigation.
Purpose of the Study:
- To assess the pathogenicity of GB virus C (GBV-C) on liver function.
- To evaluate the effect of GBV-C co-infection on the clinical features and prognosis of patients with hepatitis B and C.
Main Methods:
- Cross-sectional and prospective cohort studies were conducted.
- GBV-C RNA was detected using reverse transcriptase nested polymerase chain reaction (RT-nPCR).
- Liver function was assessed using an automated analyzer.
Main Results:
- GBV-C prevalence was high (16.2-28.8%) in high-risk populations.
- GBV-C co-infection did not alter clinical features, liver function, or prognosis in hepatitis B or C patients.
- Hemodialysis patients with GBV-C alone showed no liver functional changes.
Conclusions:
- GBV-C demonstrates no significant pathogenicity on the liver.
- GBV-C is unlikely to be classified as a hepatitis virus based on these findings.
Aim:
To determine the pathogenicity of GB virus C (GBV-C) on liver and the effects of its co-infection on the clinical features and prognosis of patients with hepatitis B and C.
Methods:
Cross-sectional study was carried out in 413 patients with acute, chronic hepatitis B or liver cirrhosis, and in 67 hemodialysis patients. A 20-month prospective cohort study was carried out in 95 hepatitis B and 80 hepatitis C patients. A reverse transcriptase nested polymerase chain reaction (RT-nPCR) of the 5'-noncoding region was used to detect circulating GBV-C RNA. Liver function was determined by an automated analyzer for all patients.
Results:
The prevalence of GBV-C in the high-risk populations with the virus transmitted via blood was high, ranging from 16.2 to 28.8 %. Co-infection with GBV-C in hepatitis B patients did not affect the clinical features of the disease or liver function. The dialysis patients infected with GBV-C alone did not develop functional changes to the liver. Prospective cohort study showed that GBV-C co-infection did not affect the clinical features, prognosis or negative serum conversion rate of chronic hepatitis B and C.
Conclusion:
The results suggest that GBV-C has no marked pathogenicity on liver, so it may not be a hepatitis virus.
Related Concept Videos
Hepatitis
Cytomegalovirus Disease
Viral Hepatitis I: Introduction

